Compare · GILD vs OKYO
GILD vs OKYO
Side-by-side comparison of Gilead Sciences Inc. (GILD) and OKYO Pharma Limited (OKYO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GILD and OKYO operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $184.47B, about 2253.2x OKYO ($81.9M).
- Over the past year, GILD is up 29.7% and OKYO is down 32.8% - GILD leads by 62.5 points.
- GILD has been more active in the news (12 items in the past 4 weeks vs 8 for OKYO).
- GILD has more recent analyst coverage (25 ratings vs 2 for OKYO).
- Company
- Gilead Sciences Inc.
- OKYO Pharma Limited
- Price
- $148.78+1.33%
- $1.60+5.26%
- Market cap
- $184.47B
- $81.9M
- 1M return
- +13.98%
- -1.84%
- 1Y return
- +29.69%
- -32.77%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1992
- 2022
- News (4w)
- 12
- 8
- Recent ratings
- 25
- 2
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
OKYO Pharma Limited
OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. It is developing OK-101 for the treatment of dry eye disease; and OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. The company is also developing chemerin and chemerin analogues to treat the cytokine release syndrome associated with COVID-19 infections and other conditions, such as acute respiratory distress syndrome. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
Latest GILD
- European Commission Expands Role of Gilead’s Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer Across PD-L1 Status
- Director Bluestone Jeffrey exercised 5,000 shares at a strike of $67.04 and sold $725,078 worth of shares (5,000 units at $145.02) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Financial Officer Dickinson Andrew D sold $415,080 worth of shares (3,000 units at $138.36) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 165,646 units (SEC Form 4)
- Chief Comm & Corp Aff Officer Mercier Johanna exercised 25,000 shares at a strike of $67.07 and sold $3,853,908 worth of shares (28,000 units at $137.64) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 118,234 units (SEC Form 4)
- EVP Gen Counsel, Legal & Comp Cain Wettan Keeley M covered exercise/tax liability with 2,908 shares and converted options into 6,002 shares, increasing direct ownership by 58% to 8,454 units (SEC Form 4)
- SEC Form S-3ASR filed by Gilead Sciences Inc.
- SEC Form 10-Q filed by Gilead Sciences Inc.
- CORRECTING and REPLACING Gilead Sciences Announces Second Quarter 2026 Financial Results
- Chairman & CEO O'Day Daniel Patrick sold $1,954,694 worth of shares (15,000 units at $130.31) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 592,133 units (SEC Form 4)
- Gilead Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
Latest OKYO
- Amendment: SEC Form 20-F/A filed by OKYO Pharma Limited
- Amendment: CHIEF DEVELOPMENT OFFICER Jacob Gary S bought $4,900 worth of shares (3,500 units at $1.40), increasing direct ownership by 3% to 112,420 units (SEC Form 4)
- Amendment: CHIEF EXECUTIVE OFFICER Dempsey Robert John bought $23,085 worth of shares (15,000 units at $1.54) (SEC Form 4)
- Amendment: Director Brancaccio John P bought $7,385 worth of shares (5,000 units at $1.48), increasing direct ownership by 17% to 35,201 units (SEC Form 4)
- Amendment: Chief Scientific Officer Patil Rajkumar V. bought $5,011 worth of shares (3,363 units at $1.49), increasing direct ownership by 20% to 20,030 units (SEC Form 4)
- Amendment: Director Cerrone Gabriele M bought $35,000 worth of shares (25,000 units at $1.40) (SEC Form 4)
- Amendment: Director Cerrone Gabriele M bought $32,625 worth of shares (22,500 units at $1.45) (SEC Form 4)
- Amendment: CHIEF MEDICAL OFFICER Mantelli Flavio bought $28,000 worth of shares (20,000 units at $1.40) (SEC Form 4)
- Chief Scientific Officer Patil Rajkumar V. was granted 3,363 shares, increasing direct ownership by 20% to 20,030 units (SEC Form 4)
- New insider Patil Rajkumar V. claimed ownership of 16,667 shares (SEC Form 3)